How Far Could Bitcoin’s Price Plummet? Top Analysts Reveal Their Projections
Bitcoin's rollercoaster ride continues as market leaders weigh in on potential downside risks
The Bearish Scenario Unfolds
Major financial institutions and crypto analysts are mapping out worst-case scenarios for Bitcoin's price trajectory. While some predict modest corrections, others see potential for significant declines based on technical indicators and macroeconomic pressures.
Technical Analysis Points to Key Levels
Chart patterns and historical support zones suggest several critical price floors that could come into play. Fibonacci retracement levels and moving averages provide additional context for where buying interest might resurface.
Macroeconomic Headwinds Mount
Interest rate decisions, regulatory uncertainty, and traditional market volatility continue to cast shadows across the crypto landscape. These external factors could accelerate any downward momentum.
The Silver Lining Perspective
Despite the gloomy forecasts, veteran crypto traders see potential buying opportunities at lower levels. Market cycles have historically rewarded those who bought during fear-driven selloffs.
As one analyst quipped: 'Wall Street still thinks crypto volatility is a bug rather than a feature—meanwhile, we're loading up our bags during these temporary discounts.' Sometimes the smartest money moves look like madness to traditional finance types.
TLDR
- Olema Pharmaceuticals announced a public offering of common stock and pre-funded warrants
- All securities will be sold by Olema, with proceeds going to the company
- Underwriters will receive a 30-day option to purchase up to 15% additional shares
- OLMA stock fell between 6.9% and 7.2% in after-hours trading following the announcement
- TD Cowen is serving as the book-running manager for the offering
Olema Pharmaceuticals stock took a hit in after-hours trading Tuesday after the company revealed plans for a public offering. The clinical-stage biopharmaceutical firm saw shares fall roughly 7% following the announcement.
Olema Pharmaceuticals, Inc., OLMA
The company plans to sell common stock to investors. For certain buyers, Olema will offer pre-funded warrants as an alternative.
All securities in the proposed offering will come from Olema itself. This means the company will receive the proceeds from the sale.
The offering includes a standard greenshoe provision. Underwriters will get a 30-day option to buy up to 15% more shares than initially offered.
This option covers both common shares and shares underlying the pre-funded warrants. TD Cowen will act as the book-running manager for the deal.
Market Response and Offering Details
The after-hours decline reflects investor concerns about share dilution. When companies issue new stock, existing shareholders own a smaller percentage of the company.
Olema has not disclosed the size of the offering. The company also hasn’t announced pricing terms for the shares or warrants.
The firm emphasized that the offering remains subject to market conditions. There’s no guarantee the deal will close or on what terms.
Company Background and Recent Activity
Olema develops targeted therapies for breast cancer patients. The company maintains a development pipeline focused on this treatment area.
Trading on the Nasdaq under ticker OLMA, the stock closed regular trading before the announcement. The post-market reaction came swiftly after the news broke.
The company made the announcement on November 18, 2025. The offering timing will depend on market conditions and investor demand.
Pre-funded warrants give investors the right to buy shares at a minimal exercise price. These instruments are often used when investors want exposure but face regulatory restrictions on ownership percentages.
The 30-day greenshoe option is standard practice in public offerings. It allows underwriters to stabilize the stock price if needed.
Olema will use the proceeds for general corporate purposes. The exact amount raised will depend on final pricing and the number of shares sold.
